Testosterone transdermal (FemTestosterone TDS) - Labtec

Drug Profile

Testosterone transdermal (FemTestosterone TDS) - Labtec

Alternative Names: FemTestosterone TDS

Latest Information Update: 11 May 2006

Price : $50

At a glance

  • Originator Labtec
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Female sexual dysfunction; Menopausal syndrome

Most Recent Events

  • 11 May 2006 Discontinued - Preclinical for Menopausal syndrome in Europe (Transdermal)
  • 11 May 2006 Discontinued - Preclinical for Female sexual dysfunction in Europe (Transdermal)
  • 07 Sep 2000 This product is available for licensing (http://www.labtec-pharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top